8-K: VBI Vaccines Faces Delisting from Nasdaq Amid Restructuring Proceedings

VBI Vaccines Inc. has initiated restructuring proceedings under the Companies' Creditors Arrangement Act in Canada and Chapter 15 of the U.S. Bankruptcy Code, leading to its delisting from Nasdaq.

Summary

• VBI Vaccines Inc. has commenced voluntary restructuring under the Companies' Creditors Arrangement Act (CCAA) in Canada.
• The company has also sought protection under Chapter 15 of the U.S. Bankruptcy Code.
• The company's common shares will be delisted from Nasdaq, with trading suspended on August 8, 2024.
• The delisting is due to the company's restructuring, concerns about residual equity for existing shareholders, and non-compliance with Nasdaq listing rules regarding minimum stockholders' equity and bid price.
• VBI does not intend to appeal the delisting and does not plan to list on another exchange.
• The company expects to cease reporting as a public company.
• The company cautions that trading in its securities is highly speculative during the restructuring.

Sentiment

Score: 2

Explanation: The document indicates a very negative situation for the company, with restructuring, delisting, and warnings about speculative trading. The company's future is highly uncertain.

Negatives

• VBI Vaccines is undergoing restructuring proceedings under CCAA and Chapter 15.
• The company's shares will be delisted from Nasdaq.
• Trading in the company's securities is highly speculative and risky.
• The company has been non-compliant with Nasdaq listing rules regarding minimum stockholders' equity and bid price.
• The company expects to cease reporting as a public company.

Risks

• The restructuring proceedings may not be successful.
• There are risks associated with the company's ability to complete a sale process under Chapter 15, CCAA, and Israeli Insolvency Law.
• The company's liquidity and results of operations could be adversely affected by the restructuring.
• There is a risk of employee attrition and difficulty retaining key personnel.
• The company may face challenges maintaining relationships with suppliers, customers, and other third parties.
• The company may face increased administrative and legal costs related to the restructuring.
• Trading prices for the company's securities may bear little or no relationship to the actual value realized by holders.

Future Outlook

The company is undergoing restructuring and expects to cease reporting as a public company. The future of the company is uncertain and dependent on the outcome of the restructuring proceedings.

Management Comments

• The company cautions that trading in its securities during the restructuring is highly speculative and poses substantial risks.
• The company urges extreme caution with respect to existing and future investments in its securities.

Industry Context

The biopharmaceutical industry is highly competitive and subject to significant risks, including clinical trial failures, regulatory hurdles, and financial challenges. VBI's restructuring highlights the financial pressures that some companies in this sector face, especially those with limited commercialized products.

Comparison to Industry Standards

• Many biopharmaceutical companies face challenges in maintaining Nasdaq listing compliance, particularly those in the development stage with limited revenue.
• Restructuring and bankruptcy filings are not uncommon in the biotech sector, especially when companies face financial difficulties or clinical trial setbacks.
• Companies like VBI, which are focused on vaccine development, often have high research and development costs and may struggle to achieve profitability quickly.
• The delisting from Nasdaq is a significant setback, as it reduces access to capital and investor confidence.

Legal Proceedings

• The company has commenced restructuring proceedings under the Companies' Creditors Arrangement Act in Canada.
• The company has sought protection under Chapter 15 of the U.S. Bankruptcy Code.
• The company intends to seek protection under the Israeli Insolvency Law.

Stakeholder Impact

• Shareholders face significant risks and potential loss of investment due to the restructuring and delisting.
• Employees may experience uncertainty and potential job losses due to the restructuring.
• Suppliers and customers may face disruptions due to the company's financial difficulties.
• Creditors face uncertainty regarding the recovery of their debts.

Next Steps

• The company will continue with its restructuring proceedings under CCAA, Chapter 15, and Israeli Insolvency Law.
• The company will seek court approvals for its restructuring plans.
• The company will proceed with a sale and investment solicitation process.
• The company will cease trading on Nasdaq on August 8, 2024.

Key Dates

Keywords

restructuring, delisting, bankruptcy, CCAA, Chapter 15, Nasdaq, VBI Vaccines, insolvency, securities, biopharmaceutical